Guardant Health, Inc. - Common Stock (NQ:GH)

169.08 +6.14 (+3.77%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

October 20, 2026

From Guardant Health, Inc.

Via Business Wire

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗

October 19, 2026

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Via MarketBeat

Topics Artificial Intelligence

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

October 15, 2026

From Guardant Health, Inc.

Via Business Wire

3 of Wall Street’s Favorite Stocks That Fall Short

October 15, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗

July 30, 2026

Via Chartmill

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

October 08, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

October 08, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

October 05, 2026

From Guardant Health, Inc.

Via Business Wire

3 Cash-Burning Stocks with Questionable Fundamentals

October 05, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

Via StockStory

Topics Bankruptcy Supply Chain

1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore

September 29, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

September 21, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Topics Credit Cards

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

September 15, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a...

Via StockStory

Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

September 14, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

September 09, 2026

From Guardant Health, Inc.

Via Business Wire

Business Insider Names Guardant Health One of America's Most Innovative Businesses

September 08, 2026

From Guardant Health, Inc.

Via Business Wire

1 Growth Stock to Add to Your Roster and 2 We Turn Down

September 08, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

September 04, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

September 01, 2026

From Guardant Health, Inc.

Via Business Wire

Why Rule Breakers Buy a Stock That's Already "Won" ↗

August 31, 2026

You found a great company, then watched it double before you got round to buying.

Via The Motley Fool

Topics Death

Guardant Health to Appeal Federal District Court Judgment

August 24, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate ↗

August 14, 2026

Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs...

Via MarketBeat

Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million ↗

August 12, 2026

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

Via The Motley Fool

Topics Regulatory Compliance

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health (GH) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Shield screening volumes more than doubled, with UnitedHealth coverage now active.

Via The Motley Fool

Topics Earnings

2 Cash-Burning Stocks to Target This Week and 1 We Find Risky

August 03, 2026

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...

Via StockStory

Topics Energy

GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth

August 01, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $33...

Via StockStory

Guardant Health Q2 Earnings Call Highlights ↗

July 31, 2026

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses....

Via MarketBeat

Topics Earnings

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

July 30, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $3...

Via StockStory

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

July 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

July 29, 2026

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.